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Abstract 
In the present study we analyzed immuno-
histochemical expression of MAGE-A 3/4 and
NY-ESO-1 in 55 samples of esophageal squa-
mous  cell  carcinomas  (ESCC)  and  their
respective  lymph  node  metastases.  To  our
knowledge this is the first study to assess and
compare the expression of these antigens in
ESCC lymph node metastases.
Fifty (90.9%) primary ESCC were positive
for MAGE-A 3/4 and 53 (96.6%) were positive
for NY-ESO-1. MAGE-A 3/4 was expressed in all
lymph  node  metastases  and  the  intensity  of
expression was high in a majority of cases. NY-
ESO-1 was negative in 2 (7.1%) lymph nodes
metastases, while the reaction was predomi-
nantly moderate in the positive group. In pri-
mary tumors MAGE-A 3/4 showed a significant-
ly higher intensity of expression compared to
NY-ESO-1  (P=0.047),  while  in  lymph  node
metastases the intensity of expression was not
significantly  different  (P=0.387).  Primary
tumors with and without lymph node metas-
tases  showed  no  significant  differences  in
MAGE-A  3/4  (P=0.672)  and  NY-ESO-1
(P=0.444) expression. Intensity of MAGE-A 3/4
(P=0.461)  and  NY-ESO-1  (P=0.414)  expres-
sion in primary tumors was not significantly
different compared to the expression in their
respective  lymph  nodes  metastases.
Expression of MAGE-A 3/4 in primary tumors
showed  significant  positive  correlation  with
primary  tumor  expression  of  NY-ESO-1
(P=0.021) but no significant correlation with
the expression of MAGE-A 3/4 in lymph node
metastases (P=0.056). Expression of NY-ESO-
1 in primary tumors showed significant posi-
tive  correlation  with  the  expression  of  NY-
ESO-1  in  lymph  node  metastases  (P=0.001)
and  significant  negative  correlation  with
patients’ age (P<0.001). Expression of MAGE-
A  3/4  and  NY-ESO-1  in  primary  tumors  and
lymph node metastases showed no significant
correlation  with  prognostic  parameters  such
as tumor grade and TNM stage (P>0.05). We
have shown different levels of MAGE-A 3/4 and
NY-ESO-1 expression in almost all specimens
of primary tumor and lymph node metastases,
suggesting that ESCC may be possible target of
immunotherapy  and  anti-tumor  vaccination.
High levels of expression in lymph node metas-
tases indicate possible clinical benefit of post-
operative vaccine with MAGE-A3 and NY-ESO-
1 in advanced stage of disease. 
Introduction
Esophageal  squamous  cell  carcinoma
(ESCC) accounts for up to 6% of all gastroin-
testinal cancers. It has a highly unfavorable
prognosis with a five-year survival rate of less
than 10%. Due to current lack of early screen-
ing  strategies,  ESCC  often  presents  in  an
advanced stage at the time of diagnosis. As a
result, its mortality rate is almost equal to its
incidence (5 per 100,000 population).1 Current
treatment has not provided much hope for a
positive outcome, and a great deal of research
is under way with the scope of detecting new
therapeutic methods. 
High risk of metastatic recurrence suggests
that cell dissemination may occur early in the
course  of  ESCC;  thus,  it  seems  that  active
immunotherapy  may  deserve  a  place  among
treatment modalities.2
Tumor associated antigens (TAA) are specific
antigens that may be recognized by cytotoxic T
lymphocytes when presented within the major
histocompatibility complex (MHC) class I mol-
ecules. Among tumor antigens, cancer/ testis
antigens (CTA) such as MAGE and NY-ESO-1
have received particular attention as potential
targets  for  vaccine-based  immuno  therapy  of
cancer because they are not expressed in nor-
mal human tissues, with the exception of male
germline cells and placenta, and are activated
in a number of tumors.3,4
The MAGE genes are the best characterized
members of the CTA family. Currently, there
are 23 related MAGE genes divided into four
clusters  on  chromosome  X.5 More  recently,
monoclonal antibodies to certain MAGE anti-
gens have been developed, allowing for their
immunohistochemical localization within neo-
plastic  tissues  and  the  pattern  of  antigen
expression was described in a subset of uter-
ine  malignancies,6 skin  melanoma,7 lung,8
renal9 and esophageal carcinomas.10-14
NY-ESO-1  is  another  member  of  the  CTA
family  that  was  originally  isolated  from
esophageal carcinoma. It is one of the most
immunogenic CTA known to date. NY-ESO-1
elicits a strong, integrated humoral and cellu-
lar immune response in a high proportion of
patients  with  NY-ESO-1-expressing  tumors.15
Expression  of  NY-ESO-1  in  normal  tissue  is
restricted to the testis. Its expression has been
described in a number of malignancies includ-
ing lung,8 renal,9 prostate,16 penile squamous17
and esophageal carcinomas.14,18-20
Recent studies have outlined MAGE and NY-
ESO-1  expression  as  a  potential  target  in
immunotherapy  and  anti-tumor  vaccina-
tion.14,21-24
In this study we analyzed MAGE-A 3/4 and
NY-ESO-1  immunohistochemical  expression
in ESCC samples and their lymph node metas-
tases,  in  order  to  determine  the  connection
between individual antigen expression in pri-
mary and metastatic lesions. In addition, the
expression of mentioned antigens was corre-
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Department  of  Surgery,  Sestre  milosrdnice
University Hospital, Zagreb, between January
1, 2003 and December 31, 2007 were included
in the study. None of the patients received pre-
operative chemotherapy or radiotherapy. There
were 8 (14.5%) female and 47 (85.5%) male
patients,  aged  38  to  73  years  (mean  57.2
years). Tumor diameter varied from 1.4 to 10
cm (mean 3.6 cm). Eighteen (32.7%) tumors
were located in the upper, 32 (58.2%) in the
middle and 5 (9.1%) in the lower part of the
esophagus. The pathologic stage of each tumor
at the time of operation was defined according
to the TNM system.25 There were 4 (7.3%) T1,
20 (36.3%) T2, 28 (50.9%) T3 and 3 (5.5%) T4
tumors. Twenty eight (50.9%) patients had one
or more lymph node metastases. All dissected
lymph  nodes  were  completely  processed  for
pathological examination. The number of dis-
sected lymph nodes varied from 3 to 24 (mean
10.5 nodes). Three to 22 lymph nodes (mean
9.8 nodes) were dissected in cases with nega-
tive  lymph  nodes,  and  4  to  24  lymph  nodes
(mean  11.1  nodes)  in  cases  with  positive
lymph  nodes.  In  cases  with  positive  lymph
nodes, 1 to 12 nodes (mean 3.2 nodes) were
affected by tumor. Each tumor also received a
histological  grade  based  on  parameters  of
mitotic activity, anisonucleosis and degree of
differentiation,  as  described  in  the  World
Health  Organization  classification.1 Seven
(12.7%)  tumors  were  grade  1,  32  (58.2%)
grade 2 and 16 (29.1%) grade 3.  
Methods
Tumors were fixed in 10% buffered formalin
for approximately 24 h, cut at 3-4 milimeters
and sampled in 3-7 sections. The specimens
were embedded in paraffin, routinely cut and
stained with hematoxylin and eosin (H&E). In
each  case,  the  available  H&E  sections  were
reviewed and slides with the deepest portion of
tumor penetration were selected for immuno-
histochemical analysis.
Two  monoclonal  antibodies  were  used  to
determine the expression of analyzed proteins
in primary tumors and lymph node metastases
(both  antibodies  are  gift  from  Dr.  Spagnoli,
Basel,  Switzerland).  57B  was  generated  on
immunization  of  mice  with  recombinant
MAGE-A3.26 However, this antibody recognizes
a variety of MAGE-A molecules, and it is con-
sidered a multi-MAGE-A-specific reagent, but a
recent analysis indicates it to be mainly reac-
tive to MAGE-A3 and MAGE-A4.27,28 D8.38 anti-
body,  recognizing  NY-ESO-1  and  its  homolo-
gous  LAGE-1  CTA,  has  been  previously
described.29 Tissue sections of 3-5 ʼm thick-
ness were cut from paraffin embedded tissue
blocks, placed on object slides (Menzel-Glaser,
Braunschweig,  Germany),  and  incubated  for
20 min in a thermostat at 60°C. The sections
were  then  deparaffinized  and  incubated  for
3ﾥ5 min in 10 mmol/L of citrate buffer (pH6.0)
in a microwave oven at 800 W. Subsequently,
tissue  slides  were  washed  with  phosphate
buffered  saline  (PBS)  buffer  (pH  7.2),  and
endogenous peroxidase activity was blocked by
a  5-min  treatment  with  hydrogen  peroxide
(No.  S2023,  Dako,  Carpinteria,  CA,  USA).
Slides were then washed with PBS-buffer and
incubated for 90 min with MAGE-A 3/4 57B or
NY-ESO-1  D8.38  undiluted  supernatants  at
room  temperature.  After  washing  in  PBS,
slides  were  incubated  with  a  secondary
biotinylated antibody (No. K0690, Dako) for 30
min. Slides were then washed with PBS-buffer
and treated with streptavidin-horseradish per-
oxidase (No. K0690, Dako) for 30 min. Tissue
sections  were  washed  once  more  in  PBS-
buffer,  and  then  Chromogen  (No.  K3468,
Dako)  was  added  for  5  min.  Slides  were
washed in distilled water, stained with hema-
toxylin (No. S2020, Dako) for 1 min, washed
with  water,  dehydrated  with  alcohol  (96%),
cleared with xylene, and mechanically covered. 
Melanoma and testicular tissues expressing
CTAs were used as positive controls. As a neg-
ative control, we replaced primary antibodies
with  isotype  matched  immunoglobulins.  In
addition, both antibodies were tested on nor-
mal  esophageal  tissue  (resection  margins)
and lymph node without tumor where showed
no positive reaction.
The  positive  cells  were  scored  in  whole
tumor at x200 magnification on chosen slides.
To evaluate the level of MAGE-A 3/4 and NY-
ESO-1 protein expression, percentages of pos-
itive-staining cells and the staining intensity
were graded on a scale of 0-3. Staining per-
centage  was  determined  as:  0=0%  positive
cells; 1 = up to 10% positive cells; 2≥10 to 50%
positive  cells;  and  3≥50%  positive  cells.
Staining intensity was denoted as: 0= no stain-
ing; 1= weak staining; 2= moderate staining;
3= strong staining. For each sample, staining
percentage and staining intensity scores were
multiplied  to  give  the  staining  index.
Immunohistochemical  staining  index  (ISI)
was labelled as: 0= zero; 1-3 = low; 4-6 = mod-
erate and 9= high.
All  samples  were  examined  independently
by  three  observers  and  any  difference  was
resolved by a joint review.
Statistical analysis
Smirnov-Kolmogorov test was used to ana-
lyze data distribution prior to statistical analy-
sis. Statistical analysis was performed using
ˇ2-test, Fischer’s exact test, Pearson correla-
tion test and Spearman rank correlation coeffi-
cients. Statistical significance was determined
if the 2-sided value of a test was less than 0.05.
Statistical  analyses  were  performed  using
SPSS  15,  Statistical  Package  (SPSS  Inc,
Chicago, IL, USA).
Results
Immunohistochemical expression results of
primary  tumor  and  lymph  node  metastasis
specimens are summarized in Table 1 and 2.
Fifty (90.9%) primary ESCCs were positive for
MAGE-A 3/4 and 53 (96.6%) were positive for
NY-ESO-1.  A  strong  immunohistochemical
reaction  for  MAGE-A  3/4  and  NY-ESO-1  was
observed in 30 (54.6%) and 18 (32.7) primary
ESCCs, respectively. 
MAGE-A 3/4 was expressed in all lymph node
metastases  and  the  intensity  of  expression
was high in a majority of cases. NY-ESO-1 was
negative in 2 (7.1%) lymph node metastases,
while the reaction was predominantly moder-
ate in the positive group.
The  immunohistochemical  expression  of
MAGE-A 3/4 and NY-ESO-1 was restricted to
tumor cells and cytoplasmic, both in primary
tumors and in lymph node metastases (Figure
1 A, B, C, D). In primary tumors, MAGE-A 3/4
showed  a  significantly  higher  intensity  of
expression compared to NY-ESO-1 (P=0.047),
whereas  lymph  node  metastases  showed  no
significant  difference  in  the  intensity  of
expression  (P=0.387).  Primary  tumors  with
and without lymph node metastases showed no
significant  difference  in  MAGE-A  3/4
(P=0.672)  and  NY-ESO-1  (P=0.444)  expres-
sion. Intensity of MAGE-A 3/4 (P=0.461) and
NY-ESO-1  (P=0.414)  expression  in  primary
tumors  was  not  significantly  different  com-
pared  to  the  expression  in  corresponding
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Table  1.  Immunohistochemical  staining
index of MAGE 3/4 and NY-ESO-1 in pri-
mary esophageal squamous cell carcinoma.
ISI MAGE 3/4 NY-ESO-1
0 5 (9.1%) 2 (3.6%)
1 7 (12.7%) 19 (34.6%)
2 13 (23.6%) 16 (29.1%)
3 30 (54.6%) 18 (32.7%)
Total 55 (100%) 55 (100%)
ISI, immunohistochemical staining index.
Table  2.  Immunohistochemical  staining
index  of  MAGE  3/4  and  NY-ESO-1  in
lymph node metastase.
ISI MAGE 3/4 NY-ESO-1
0 0 (0%) 2 (7.1%)
1 8 (28.6%) 8 (28.6%)
2 8 (28.6%) 13 (46.4%)
3 12 (42.8%) 5 (17.9%)
Total 28 (100%) 28 (100%)
ISI, immunohistochemical staining index.[European Journal of Histochemistry 2011; 55:e7] [page 41]
lymph node metastases.
Expression  of  MAGE-A  3/4  and  NY-ESO-1
showed significant positive correlation within
the primary tumor (P=0.021), but no signifi-
cant correlation within lymph node metastases
(P=0.056). Also, there was no correlation of
MAGE-A 3/4 expression in the primary tumor
and  lymph  node  NY-ESO-1  expression
(P=0.978), patient age (P=0.904), patient sex
(P=0.499), tumor grade (P=0.945), T classifi-
cation (P=0.589), lymph node status (N classi-
fication) (P=0.569) and distant metastasis (M
classification) (P=0.876).
Expression  of  NY-ESO-1  in  the  primary
tumor showed significant positive correlation
with NY-ESO-1 lymph node metastasis expres-
sion (P=0.001) and significant negative corre-
lation with patients’ age (P<0.001). Intensity
of NY-ESO-1 primary tumor expression corre-
sponded to the intensity of lymph node metas-
tasis expression. Also, the expression of NY-
ESO-1 in primary tumors was much higher in
younger patients.
Patient’s  sex  (P=0.390),  tumor  grade
(P=0.962), T classification (P=0.796), N clas-
sification  (P=0.779)  and  M  classification
(P=0.437)  showed  no  significant  correlation
with expression of NY-ESO-1 in the primary
tumor.
Significant correlation between expression
of  MAGE-A  3/4  and  NY-ESO-1  in  the  lymph
node metastasis was not found (P=0.137). In
addition,  the  expression  of  MAGE-A  3/4  and
NY-ESO-1 in lymph node metastases did not
significantly  correlate  with  patient  age
(P>0.05), patient sex (P>0.05), tumor grade
(P>0.05), T classification (P>0.05), N classifi-
cation (P>0.05) or M classification (P>0.05).
Discussion
Several studies have analyzed the expres-
sion of MAGE-A and NY-ESO-1 in ESCC.10-14,18-20
To  our  knowledge,  this  is  the  first  study  to
assess and compare the expression of MAGE-A
and  NY-ESO-1  in  ESCC  lymph  node  metas-
tases. 
MAGE-A was detected in 50-84% of ESCC,
according to different studies.10-14
In our study, MAGE-A 3/4 was expressed in
90.9% primary ESCC and all lymph node metas-
tases. MAGE-A 3/4 was similarly expressed in
primary  tumor  with  and  without  metastases
and the intensity of expression was not signif-
icantly different between primary tumors and
corresponding  lymph  nodes  metastases.  Our
results  are  most  similar  to  the  results  pub-
lished by Quillien et al.,10 who assessed the
expression of MAGE-A 1, 2, 3 and 4 genes in 49
ESCC samples by RT-PCR and PCR amplifica-
tion. MAGE-A 1 was expressed in 53%, MAGE-A
2 in 49%, MAGE-A 3 in 47% and MAGE-A 4 in
71% tumors, respectively. Eighty four percent
of tumors expressed one or more of the inves-
tigated MAGE genes.10
In another similar study also conducted by
RT-PCR, MAGE-A 1, 2 and 3 genes were ana-
lyzed in 42 surgical samples and in 12 cell lines
of human esophageal carcinoma.11 MAGE-A 1,
2, and 3 genes were expressed in 26 (62%), 18
(43%) and 24 (57%) tumor specimens, respec-
tively.  Thirty  three  of  42  (79%)  carcinomas
expressed at least one MAGE gene. In normal
esophageal tissue, MAGE-A expression was not
found. In cell lines, expression of MAGE-A 1, 2,
and 3 was recognized in 5, 4 and 4 cell lines,
respectively.11
Zambon et al.12 analyzed MAGE, BAGE, and
GAGE  gene  expression  in  24  ESCC  and  24
esophageal adenocarcinomas by RT-PCR and
correlated their expression patterns with prin-
cipal prognostic parameters and long term sur-
vival. Sixteen ESCC (67%) and 9 adenocarci-
nomas  (38%)  expressed  at  least  one  of  the
studied genes. The expression of each MAGE
gene in the two histologic types was not signif-
icantly different, with the exception of MAGE-
4,  which  was  expressed  more  frequently  in
ESCC samples than in adenocarcinoma sam-
ples. BAGE and GAGE expression was low. In
each sample it was associated with the expres-
sion of at least one MAGE gene. Gene expres-
sion was not correlated with disease progres-
sion, TNM factors or survival.12
Expression of MAGE-A proteins in ESCC was
also studied by immunohistochemistry.13,14
Immunohistochemical  analysis  of  MAGE-A
protein expression in 98 patients with ESCC or
adenocarcinoma showed positive reaction in
five out of 32 adenocarcinomas (15%) and in
33 out of 66 (50%) ESCC.13
Similar results of MAGE-A protein expres-
sion in esophageal carcinoma was published
by  Akcakanat  et  al.14 They  examined  the
immunohistochemical expression of CTA pro-
teins in 213 patients with esophageal carcino-
ma. GAGE, NY-ESO-1 and MAGE-A were hetero-
geneously  expressed  in  42  (20%),  44  (21%)
and 111 (52%) tumors, respectively, whereas
SSX expression was not detected. Expression
of  MAGE  showed  correlation  with  those  of
GAGE and NY-ESO-1.14
We also found significant positive correla-
tion  between  MAGE-A  3/4  and  NY-ESO-1
expression in primary tumors, and no correla-
tion in lymph node metastases expression. The
level  of  MAGE-A  3/4  expression  in  primary
tumor and corresponding lymph nodes metas-
tases approached the threshold for significant
correlation, but did not reach it (P=0.056).  
The lowest expression of NY-ESO-1 in ESCC
was  reported  in  the  previously  mentioned
immunohistochemical  study  conducted  by
Akcakanat  et  al.14 Similar  expression  was
observed by Mashino et al. who investigated 46
samples of esophageal carcinoma by RT-PCR
analysis  and  found  expression  in  11  (24%)
esophageal carcinomas.18
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Figure 1. Immunohistochemical expression of MAGE–A 3/4 and NY-ESO-1 in esophageal
squamous cell carcinoma and lymph node metastasis.  Expression of A) MAGE-A 3/4 and
B) NY-ESO-1 in a primary tumor was cytoplasmic and limited to tumor cells. Similar
immunohistochemical reaction for C) MAGE-A 3/4 and D) NY-ESO-1 was also observed
in corresponding lymph node metastases. Scale bar = 300 µm. [page 42] [European Journal of Histochemistry 2011; 55:e7]
In another larger study which included 123
ESCCs, the expression of NY-ESO-1 mRNA was
analyzed  by  conventional  and  real-time  RT-
PCR and the expression of protein by immuno-
histochemistry and Western blot. In addition,
sera and peripheral blood lymphocytes from 51
patients were analyzed for the NY-ESO-1 anti-
body production by enzyme-linked immunosor-
bent assay and NY-ESO-1 T cell response by
enzyme-linked  immunospot  assay.  NY-ESO-1
mRNA was expressed in 41 (33%) carcinoma
specimens and the expression was higher in
well-differentiated and moderately differenti-
ated type of carcinoma. Also, twenty-one of 24
(87.5%) mRNA positive tumors were stained
positively by immunohistochemistry. Correla  -
tion  between  the  level  of  NY-ESO-1  mRNA
expression  and  the  degree  of  immunohisto-
chemical  positivity  was  observed.  Antibody
production  was  observed  in  2  patients  with
tumors  that  showed  protein  expression.
Survival data indicated that the survival rate
was higher in NY-ESO-1 protein-positive cases
than in negative cases, but the difference was
not statistically significant.19
Akcakanat  et  al.  analyzed  the  sera  of  69
patients with esophageal cancer for antibody
production against NY-ESO-1 by Western blot
analysis. Moreover, they also analyzed 56 tis-
sue samples for NY-ESO-1 protein expression
by  immunohistochemistry.  NY-ESO-1  protein
expression  was  found  in  18  of  56  (32%)
esophageal carcinomas. NY-ESO-1 serum spe-
cific immunoreactivity was found in 9 patients
(13%), of whom 8 were in the advanced stage
(stages III and IV). They found no relationship
between clinico-pathologic features and serum
immunoreactivity  for  NY-ESO-1.  NY-ESO-1
protein  expression  was  detected  in  three  of
five  antibody-positive  patients  whose  tissue
was available for analysis but survival analysis
showed  no  significant  difference  between
antibody-positive  and  antibody-negative
patient groups.20
In our study, the expression of NY-ESO-1 in
primary  tumor  specimens  was  higher  com-
pared to previously reported results.14,18-20 We
found only two tumors and two lymph nodes
metastases with a negative reaction for NY-
ESO-1. Currently we are not able to explain
this difference in NY-ESO-1 expression but we
believe that further investigation could resolve
this issue. We found a significant positive cor-
relation between NY-ESO-1 expression in pri-
mary tumors and corresponding lymph node
metastases. In addition, the expression of NY-
ESO-1  in  primary  tumors  was  significantly
higher in younger patients. To our knowledge
this is a first report of connection between NY-
ESO-1  expression  and  age  in  ESCC.
Expression of NY-ESO-1 diminishes with age,
which would indicate lesser immunogenicity
and  possible  worse  response  on  adjuvant
immunotherapy in older patients.  
Expression of MAGE-A 3/4 and NY-ESO-1 in
ESCC showed no significant correlation with
prognostic  parameters,  such  as  TNM  stage
and survival.11,12,14,18-20 Only one study found
the expression of NY-ESO-1 to be higher in
well-differentiated and moderately differenti-
ated ESCC. In this study, the survival rate was
higher  in  NY-ESO-1  positive  cases,  but  did
not  reach  statistical  significance.19 Our
results were similar with previous investiga-
tions and the expression of MAGE 3/4 and NY-
ESO-1  in  primary  tumors  and  lymph  node
metastases showed no influence on prognos-
tic parameters.
MAGE-A and NY-ESO-1 expression was also
analyzed in prostate carcinoma and squamous
cell carcinoma of the penis.16,17 In prostate car-
cinoma  multi-MAGE-A  and  NY-ESO-1  was
expressed  in  85.9%  and  84.8%  carcinomas
while  in  penile  carcinoma  97%  of  tumors
showed  positive  reaction  on  tested  antigens
but in both carcinomas like in ESCC, expres-
sion did not significantly correlate with prog-
nostic parameters.16,17
Recent clinical trials have demonstrated a
clinical benefit by postoperative vaccine with
MAGE-A3 in non-small cell lung cancer and in
stage IV melanoma. These trials have led to the
current Phase III trials.22,30,31
We have shown different levels of MAGE-A
3/4  and  NY-ESO-1  expression  in  almost  all
specimens of primary tumor and lymph node
metastases, suggesting that ESCC may be pos-
sible target of immunotherapy and anti-tumor
vaccination. High levels of expression in lymph
node metastases indicate possible clinical ben-
efit  of  postoperative  vaccine  with  MAGE-A3
and NY-ESO-1 in advanced stage of disease.
Moreover,  NY-ESO-1  expression  in  tumors
negatively correlated with patient age which
indicating  better  response  on  therapy  in
younger patients. 
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